Evidence map›Paper›PMID 36669780›Full record

ArticleRespiratory care2023

Effectiveness and Safety of Albuterol Solutions With and Without Benzalkonium Chloride.

Awni M Al-Subu, Eric Friestrom, Erica Terry, Miranda R Langkamp, Carolyn K Adams, Rhonda A Yngsdal-Krenz, Michael R Lasarev, Ryan L DeSanti, Joshua P Vanderloo, Monica C Bogenschutz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Awni M Al-SubuDivision of Pediatric Critical Care Medicine, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; and UW Health American Family Children's Hospital, UW Health, Madison, Wisconsin. al-subu@pediatrics.wisc.edu.
Eric FriestromUW Health University Hospital, Madison, Wisconsin.
Erica TerryLucile Packard Children's Hospital, Stanford Medicine Children's Health, Palo Alto, California.
Miranda R LangkampPediatric Respiratory Care, American Family Children's Hospital, UW Health, Madison, Wisconsin.
Carolyn K AdamsPediatric Respiratory Care, American Family Children's Hospital, UW Health, Madison, Wisconsin.
Rhonda A Yngsdal-KrenzDivision of Pediatric Critical Care Medicine, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Michael R LasarevDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin.
Ryan L DeSantiDepartment of Pediatrics, Drexel University College of Medicine, St. Christopher's Hospital for Children, Philadelphia, Pennsylvania.
Joshua P VanderlooUW Health University Hospital, Madison, Wisconsin.
Monica C BogenschutzUW Health American Family Children's Hospital, UW Health, Madison, Wisconsin.
University of Wisconsin Health · USUniversity of Wisconsin–Madison · USUniversity of Wisconsin American Family Children's Hospital · USLucile Packard Children's Hospital · USSt. Christopher's Hospital for Children · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionContinuous aerosolized β

methodsThis was a retrospective cohort study of pediatric subjects admitted to the pediatric ICU (PICU) and treated with continuous albuterol. Data were collected and compared before and after a change to benzalkonium chloride-containing solutions. Subjects who were treated with preservative-free solutions were used as control. The primary outcome was PICU and hospital LOS; secondary outcomes included the duration of continuous albuterol and use of adjunctive therapies.

resultsA total of 266 admissions were included in the study. One hundred forty subjects (52.6%) were exposed to benzalkonium chloride. Median age and severity of illness scoring were similar between groups. The initial dose of continuous albuterol was significantly higher in the benzalkonium chloride group (median 15 interquartile range [IQR] 10-20 mg/h) compared to the preservative-free group (median 10 IQR 10-20 mg/h) (

conclusionsIn contrast to published literature showing that benzalkonium chloride may be associated with a longer duration of continuous albuterol nebulization and hospital LOS, our study demonstrated that benzalkonium chloride-containing albuterol is safe for continuous nebulization in critically ill children and not associated with worse outcomes.

Indexed as

AlbuterolBenzalkonium CompoundsBronchodilator AgentsChildHeliumHumansOxygenRetrospective StudiesAlbuterolBenzalkonium CompoundsBronchodilator AgentshelioxHeliumOxygenaerosolized β2 agonistalbuterolbenzalkonium chloridecritical asthmapediatricsPICU

Identifiers

PMID36669780
PMCPMC10208994
OpenAlexW4317535897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.